


Tulathromycin A

Cat. No.:	HY-15662		
CAS No.:	217500-96-4		
Molecular Formula:	C ₄₁ H ₇₉ N ₃ O ₁₂		
Molecular Weight:	806.08		
Target:	Antibiotic; Bacterial		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (62.03 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	1.2406 mL	6.2029 mL	12.4057 mL
		5 mM	0.2481 mL	1.2406 mL	2.4811 mL
10 mM		0.1241 mL	0.6203 mL	1.2406 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.10 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.10 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.10 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Tulathromycin A (Tulathromycin), a macrolide antibiotic, inhibits protein synthesis (IC ₅₀ =0.26 μM) by targeting bacterial ribosome. Tulathromycin A is used for the research of respiratory disease in cattle and swine. Immunomodulatory effects ^[1] [2][3].
In Vitro	Tulathromycin A (Tulathromycin) represents the first member of a novel subclass of macrolides, known as triamilides ^[1] . Tulathromycin A (0.02 to 2.0 mg/mL) induces time- and concentration-dependent apoptosis in neutrophils, which enhances their subsequent clearance by macrophages ^[3] .

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	<p>In the lungs of both A pleuropneumoniae- and zymosan-challenged pigs, Tulathromycin A (2.5 mg/kg, IM) promotes leukocyte apoptosis and efferocytosis and inhibites proinflammatory leukotriene B4 production, with a concurrent reduction in leukocyte necrosis relative to that of control pigs. Tulathromycin A also attenuates the degree of lung damage and lesion progression in A pleuropneumoniae-inoculated pigs^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. Villarino N, et al. Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coli. *Antimicrob Agents Chemother.* 2012;56(8):4078-4086.
- [2]. Andersen NM, et al. Inhibition of protein synthesis on the ribosome by tildipirosin compared with other veterinary macrolides. *Antimicrob Agents Chemother.* 2012;56(11):6033-6036.
- [3]. Duquette SC, et al. Immunomodulatory effects of tulathromycin on apoptosis, efferocytosis, and proinflammatory leukotriene B4 production in leukocytes from Actinobacillus pleuropneumoniae-or zymosan-challenged pigs. *Am J Vet Res.* 2015;76(6):507-519.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA